Faculty profile

Xuesen Dong

ResearcherUrologic SciencesUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Xuesen Dong

Researcher

Urologic Sciences

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
28 publications in the last five years, latest in 2026.
Senior (last) author on 11 recent papers, a sign of leading a research group.
Principal investigator on 6 research grants (6 CIHR), most recently in 2024.
Supervised 1 trainee who won CIHR awards, most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Prostate Cancer Therapy-Resistant Prostate Cancer Cancer Biology Dna Topoisomerase Mitosis Hormone Therapy Resistance Castration Resistant Prostate Cancer

Latest papers

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.
European urology oncology · 2026
A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR.
Nature communications · 2026
Beyond Ion Channels: Emerging Roles of FGF12 in Cellular Regulation and Cancer Progression.
Cells · 2026 · senior author

All 86 publications

Latest funding

Lin28b as a therapeutic target for prostate cancer progression
CIHR · 2024 · Nominated PI
$967,726
Developing novel Lin28 inhibitors by computer-aided drug design
CIHR · 2024 · Supervisor
$120,000
Design a Double-Bolt Lock to Control Cancer Cell Growth
CIHR · 2021 · Nominated PI
$910,350

All 8 grants and awards

86 publications.

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.

Uchil A, Lacombe L, Hovington H, Brisson H, Simonyan D, Caron P, Ouellet V, Latour M, Aprikian A, Bergeron A, Chevalier S, McKercher G, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Carmel M, Hamilou Z, Trudel D, van der Kwast T, Mes-Masson AM, Dong X, Saad F, Guillemette C, Lévesque E

European urology oncology2026

DOI: 10.1016/j.euo.2025.07.014 PMID: 40998686

A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR.

Yi Y, Li Y, Wang R, Yu X, Liu Q, Yum C, Zhang Y, Qiao Y, Szczepanski A, Wu S, Li Q, Fazli L, Shen J, Wang X, Li X, Mu P, Schaeffer EM, Hundley HA, Niu H, Chinnaiyan AM, Wang L, Shi J, Jin J, Dong X, Zhao W, Chen K, Cao Q

Nature communications2026

DOI: 10.1038/s41467-026-71207-3 PMID: 41882000

Beyond Ion Channels: Emerging Roles of FGF12 in Cellular Regulation and Cancer Progression.

Huang Z, Dong X

Cells2026Senior author

DOI: 10.3390/cells15040370 PMID: 41744813

Noncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression.

Feng T, Xie N, Gao L, Jia Q, Kung SH, Morova T, Li Y, Wang L, Fazli L, Lacombe L, Guillemette C, Lévesque E, Lack NA, Qi J, Han B, Dong X

The Journal of clinical investigation2026Senior author

DOI: 10.1172/jci196495 PMID: 41343245

EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway.

Yi Y, Fry J, Yum C, Wang R, Wu S, Narayan S, Liu Q, Zhang X, Oo HZ, Xie N, Li Y, Gao X, Yu X, Hu X, Li Q, Keseroglu K, Özbudak EM, Abdulkadir SA, Chen K, Jin J, Zhao JC, Dong X, Arango D, Yang R, Cao Q

The Journal of clinical investigation2026

DOI: 10.1172/jci195840 PMID: 41252201

Corrigendum to "A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network" EBioMedicine 2018 Sep: 35: 167-177.

Lee AR, Gan Y, Tang Y, Dong X

EBioMedicine2025Senior author

DOI: 10.1016/j.ebiom.2025.105983 PMID: 41275569

FGF12 Enhances Prostate Cancer Cell Survival via the YB1-lncRNA Axis.

Huang Z, Kung SHY, Adomat H, Oo HZ, Forbes C, Hach F, Dong X

Cells2025Senior author

DOI: 10.3390/cells14221828 PMID: 41294881

Ketone drink enhances therapeutic efficacy in prostate cancer by targeting EZH2.

Yum C, Schaefer RA, Wang R, Wang TY, Lu X, Liu Q, Ren Y, Meng Q, Yang Y, Zhang X, Xiong Y, Yu X, Zhang X, Jin J, Dong X, Yi Y, Yang R, Cao Q

Oncogenesis2025

DOI: 10.1038/s41389-025-00567-0 PMID: 40651983

Corrigendum to "RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression" [Eur. Urol. 76(2) (2019) 157-166].

Li Y, Xie N, Chen R, Lee AR, Lovnicki J, Morrison EA, Fazli L, Zhang Q, Musselman CA, Wang Y, Huang J, Gleave ME, Collins C, Dong X

European urology2025Senior author

DOI: 10.1016/j.eururo.2025.04.022 PMID: 40340107

Androgen receptor-regulated lncRNA PRCAT71 promotes AR signaling through the interaction with KHSRP in prostate cancer.

Yang Y, Wang TY, Li Q, Lu J, Ren Y, Weiner AB, Fry J, Liu Q, Yum C, Wang R, Guo Q, Wan Y, Ji Z, Dong X, Lotan TL, Schaeffer EM, Yang R, Cao Q

Science advances2025

DOI: 10.1126/sciadv.adk6989 PMID: 40203114

Something wrong or missing on this profile? Suggest a correction

Xuesen Dong

Research

Latest papers

Latest funding

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.

A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR.

Beyond Ion Channels: Emerging Roles of FGF12 in Cellular Regulation and Cancer Progression.

Noncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression.

EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway.

Corrigendum to "A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network" EBioMedicine 2018 Sep: 35: 167-177.

FGF12 Enhances Prostate Cancer Cell Survival via the YB1-lncRNA Axis.

Ketone drink enhances therapeutic efficacy in prostate cancer by targeting EZH2.

Corrigendum to "RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression" [Eur. Urol. 76(2) (2019) 157-166].

Androgen receptor-regulated lncRNA PRCAT71 promotes AR signaling through the interaction with KHSRP in prostate cancer.

Frequent collaborators

Martin Gleave

Yuzhuo Wang

Artem Cherkasov

Colin Collins

Ralph Buttyan

Stephen Lye

Donna Slater

Michael Cox

Oksana Shynlova

Lucia Nappi

Paul Rennie

Chantal Guillemette

Amina Zoubeidi

Neil Fleshner

Mads Daugaard

Yu Wang

Cenk Sahinalp

Colin Collins

Olivier Barbier